Abstract:
The aim of this work was to evaluate the efficacy and safety of Immunoflazid® for the prevention of infectious diseases in children in the first year of life. Methods. A comparative controlled study in parallel groups of healthy newborns. According to the results of randomization, patients were divided into 2 groups. The study group included 39 children who are over 14 days of receiving Immunoflazid® per day. The control group consisted of 36 infants who did not receive the drug. The effectiveness of preventive measures was assessed by the
absence of disease over a period of six months follow-up. Results. Studies have shown that children of the main group in the 4-fold decreased the incidence of infectious diseases, the relative risk of disease decreased by 75%, the chances of the disease decreased to 0.03. During the administration of the drug is not registered a single case of side effects. Conclusions. Immunoflazid® – an effective and safe means of preventing infectious diseases in children in the first year of life.
